We evaluated the effect of OROS methylphenidate (MPH) on sleep quality and architecture in children with attention-deficit/hyperactivity disorder (ADHD) using both a parental sleep questionnaire and polysomnography. Twenty-four ADHD children who had no comorbid psychiatric or sleep disorders except for oppositional defiant disorder completed the 6-week, prospective, open-label, flexible-dose trial with OROS MPH (Concerta) monotherapy. After OROS MPH administration, the polysomnography data indicated that the percentage of stage 2 sleep was increased (P=0.024) and the Number of Awakenings was decreased (P=0.047). Relative to baseline, Parasomnias of the Children's Sleep Habits Questionnaire were decreased (P=0.033). Sleep Onset Latency was not changed during the treatment in general, but was increased in six children with subjective sleep difficulties (F(1)=5.832, P=0.025, eta(2)(p)=0.226). Bedtime Resistance and Sleep Onset Delay in Children's Sleep Habits Questionnaire were also increased during the treatment with OROS MPH only in individuals with sleep complaints (F1=5.001, P=0.036, eta(2)(p)=0.185; F(1)=7.237, P=0.013, eta(2)(p)=0.248). These results suggest that OROS MPH in open-label treatment does not seem to impair sleep and may even improve some aspects of sleep.

译文

:我们使用父母的睡眠问卷和多导睡眠监测仪评估了OROS哌醋甲酯(MPH)对注意力不足/多动障碍(ADHD)儿童的睡眠质量和结构的影响。除了对立违抗性疾病外,没有其他合并精神病或睡眠障碍的二十四位多动症儿童完成了为期六周的前瞻性,开放标签,灵活剂量的OROS MPH(Concerta)单药治疗试验。经OROS MPH给药后,多导睡眠图数据表明,第2阶段睡眠的百分比增加(P = 0.024),觉醒次数减少(P = 0.047)。相对于基线,儿童睡眠习惯问卷的失眠症有所减少(P = 0.033)。总体而言,治疗期间睡眠发作潜伏期没有变化,但有6名主观睡眠困难的儿童却有所增加(F(1)= 5.832,P = 0.025,eta(2)(p)= 0.226)。仅在有睡眠障碍的患者中,用OROS MPH治疗期间,儿童睡眠习惯问卷的就寝时间抵抗力和睡眠发作延迟也增加了(F1 = 5.001,P = 0.036,eta(2)(p)= 0.185; F(1)= 7.237,P = 0.013,eta(2)(p)= 0.248)。这些结果表明,开放标签治疗中的OROS MPH似乎不会损害睡眠,甚至可能改善睡眠的某些方面。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录